

**tert-Butoxycarbonyl-L-leucyl-L-alanine trichloroethyl ester (Boc-L-Leu-L-Ala-OTce)**

**Hiroyuki Oku,\* Teruya Endo,  
Keiichi Yamada and Ryoichi  
Katakai**

Department of Chemistry, Gunma University,  
Kiryu, Gunma 376-8515, Japan

Correspondence e-mail:  
oku@chem.gunma-u.ac.jp

**Key indicators**

Single-crystal X-ray study  
 $T = 173\text{ K}$   
Mean  $\sigma(\text{C}-\text{C}) = 0.009\text{ \AA}$   
R factor = 0.043  
wR factor = 0.079  
Data-to-parameter ratio = 15.7


For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The title compound,  $\text{C}_{16}\text{H}_{27}\text{Cl}_3\text{N}_2\text{O}_5$ , which is an enantiopure dipeptide trichloroethyl ester, adopts an extended conformation. The molecules are linked via  $-\text{NH}\cdots\text{O}=\text{C}$  hydrogen bonds into a unique  $\beta$ -spiral assembly along the  $c$  axis.

Received 29 July 2005  
Accepted 18 August 2005  
Online 27 October 2005


**Comment**

The 2,2,2-trichloroethyl group (-OTce) is useful for carboxyl protection in peptide synthesis (Marinier *et al.*, 1973; Olsen *et al.*, 1986; Pastuszak *et al.*, 1982; Yamada *et al.*, 2003). By using the -OTce group, the selective removal from other carboxyl protection, such as benzyl (-OBzl), can be carried out by treating the peptide with zinc powder in acetic acid under mild conditions.



There are two problems for -OTce protection, despite its usefulness. One is the significant racemization that can occur during the -OTce esterification to *N*-benzyloxycarbonyl- (*Z*-) and *N*-*tert*-butoxycarbonyl- (Boc-)  $\alpha$ -amino acids (Dhaon *et al.*, 1982; Neises & Steglich, 1978; Atherton *et al.*, 1981). The other is the oily property and difficult crystallinity of *N*-protected peptide trichloroethyl esters such as *Z*-Ala-OTce (Dhaon *et al.*, 1982), *Z*-Leu-Ala-OTce (Marinier *et al.*, 1973) and Boc-Val-Leu-OTce (Yamada *et al.*, 2003). Therefore, in this paper, to assess the enantiopurity and crystallinity, we have studied the crystal structure of the title compound, (I), as one of our synthetic fragments of cyclosporin O derivatives (Endo *et al.*, 2003).

The molecular structure of (I) is shown in Fig. 1. The molecule adopts an extended  $\beta$ -sheet conformation and molecules are tightly linked together by  $\text{N}-\text{H}\cdots\text{O}=\text{C}$  hydrogen bonds (Table 2), to form a  $\beta$ -spiral assembly along the  $c$  axis (Fig. 2). Packed in the unit cell (Fig. 3), they are tightly linked together by  $\text{N}-\text{H}\cdots\text{O}=\text{C}$  hydrogen bonds, forming an infinite spiral along the  $c$  axis. The  $\beta$ -helical structure is not common, but it is



**Figure 1**

A view of (I), with the atomic numbering scheme. Displacement ellipsoids are drawn at the 20% probability level.

sometimes observed in short peptides (Doi *et al.*, 1994; Görbitz & Gundersen, 1996; Oku *et al.*, 2003).

## Experimental

The title peptide, (I), was prepared by the coupling of Boc-Leu-OH (4.88 g, 19.0 mmol) and HCl-Ala-OTce (5.68 g, 22.8 mmol) as solution-phase synthesis. Yield 7.44 g (90%). Crystals of (I) were grown by slow diffusion of hexane vapor into a diethyl ether solution. Analytical data (melting point,  $^1\text{H}$  NMR, ESI-MS and  $[\alpha]_D^{20}$ ) are in accordance with the expected structure;  $[\alpha]_D^{20} = -46.2^\circ$  ( $c$  0.1, methanol). m.p. = 415–417 K.

### *Crystal data*


$C_{16}H_{27}Cl_3N_2O_5$   
 $M_r = 433.75$   
 Hexagonal,  $P6_5$   
 $a = 12.1055 (14) \text{ \AA}$   
 $c = 26.939 (5) \text{ \AA}$   
 $V = 3418.8 (8) \text{ \AA}^3$   
 $Z = 6$   
 $D_v = 1.264 \text{ Mg m}^{-3}$

### *Data collection*


Rigaku R-AXIS RAPID  
diffractometer  
 $\omega$  scans  
Absorption correction: none  
29240 measured reflections  
4134 independent reflections

Cu  $K\alpha$  radiation  
 Cell parameters from 21563  
 reflections  
 $\theta = 3.3\text{--}68.2^\circ$   
 $\mu = 3.85 \text{ mm}^{-1}$   
 $T = 173.1 \text{ K}$   
 Needle, colorless  
 $0.30 \times 0.01 \times 0.01 \text{ mm}$

1326 reflections with  $F^2 > 2\sigma(F^2)$   
 $R_{\text{int}} = 0.097$   
 $\theta_{\text{max}} = 68.2^\circ$   
 $h = -14 \rightarrow 14$   
 $k = -14 \rightarrow 14$   
 $l = -31 \rightarrow 32$



**Figure 2**  
A packing diagram of (I), projected down the *c* axis.



**Figure 3**  
A packing diagram of (I), projected down the  $a$  axis. Two  $\beta$ -spiral columns are shown packed in the unit cell along the  $c$  axis. Hydrogen bonds are shown as dashed lines.

Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.043$   
 $wR(F^2) = 0.079$   
 $S = 1.06$   
 4134 reflections  
 263 parameters  
 H-atom parameters constrained  
 $w = 1/[0.1\sigma(F_o^2) + 2.0]/(4F_o^2)$   
 $(\Delta/\sigma)_{\text{max}} < 0.001$   
 $\Delta\rho_{\text{max}} = 1.14 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\text{min}} = -0.65 \text{ e \AA}^{-3}$   
 Absolute structure: Flack (1983),  
 1992 Friedel pairs  
 Flack parameter: 0.05 (2)

**Table 1**  
Selected torsion angles (°).

C302—O401—C401—C402	150.4 (5)	C202—N301—C301—C302	-61.6 (6)
C401—O401—C302—C301	-178.1 (4)	C301—N301—C202—C201	178.0 (4)
C105—N201—C201—C202	-91.6 (6)	N201—C201—C202—N301	130.6 (4)
C201—N201—C105—O101	177.2 (6)	N301—C301—C302—O401	151.8 (4)

**Table 2**  
Hydrogen-bond geometry (Å, °).

D—H···A	D—H	H···A	D···A	D—H···A
N201—H10···O102 <sup>i</sup>	0.95	1.97	2.907 (5)	171
N301—H21···O201 <sup>ii</sup>	0.95	1.89	2.829 (6)	170

Symmetry codes: (i)  $+y, -x + y, +z + \frac{1}{6}$ ; (ii)  $+x - y, +x, +z - \frac{1}{6}$ .

The ratio of observed/unique reflections was relatively low (32%), although the X-ray measurement was carried out at 173 K with Cu  $K\alpha$  radiation. H atoms were positioned geometrically, with C—H = N—H = 0.95 Å, and refined using a riding model, with  $U_{iso}(\text{H})$  initially assigned to be  $1.2U_{eq}$  of the carrier atom. The absolute configuration of (I) agrees with the fact that the  $^1\text{H}$  NMR spectroscopic data detected no racemization in the preparation.

Data collection: RAPID-AUTO (Rigaku, 2003); cell refinement: RAPID-AUTO; data reduction: CrystalStructure (Rigaku, 2003); program(s) used to solve structure: SIR2002 (Burla *et al.*, 2003); program(s) used to refine structure: CRYSTALS (Betteridge *et al.*, 2003); molecular graphics: ORTEP (Johnson, 1965); software used to prepare material for publication: CrystalStructure.

HO is grateful for grants-in-aid for Scientific Research on Priority Areas (Nos. 14078101 and 16033211, Reaction Control of Dynamic Complexes) from the Ministry of Education Culture, Sports, Science and Technology, Japan.

## References

- Atherton, E., Benoiton, N. L., Brown, E., Sheppard, R. C. & Williams, B. J. (1981). *J. Chem. Soc. Chem. Commun.* **7**, 336–337.
- Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K. & Watkin, D. J. (2003). *J. Appl. Cryst.* **36**, 1487.
- Burla, M. C., Camalli, M., Carrozzini, B., Casarano, G. L., Giacovazzo, C., Polidori, G. & Spagna, R. (2003). *J. Appl. Cryst.* **36**, 1103.
- Dhaon, M. K., Olsen, R. K. & Ramasamy, K. (1982). *J. Org. Chem.* **47**, 1962–1965.
- Doi, M., In, Y., Inoue, M. & Ishida, T. (1994). *Int. J. Pept. Protein Res.* **44**, 532–538.
- Endo, T., Oku, H., Yamada, K. & Katakai, R. (2003). *Peptide Science, 2002*, edited by T. Yamada, pp. 313–316. Osaka: The Japanese Peptide Society.
- Flack, H. D. (1983). *Acta Cryst. A* **39**, 876–881.
- Görbitz, C. H. & Gundersen, E. (1996). *Acta Chim. Scand.* **50**, 537–543.
- Johnson, C. K. (1965). ORTEP. Oak Ridge National Laboratory, Tennessee, USA.
- Marinier, B., Kim, Y. C. & Navarre, J.-M. (1973). *Can. J. Chem.* **51**, 208–214.
- Neises, B. & Steglich, W. (1978). *Angew. Chem. Int. Ed. Engl.* **17**, 522–524.
- Oku, H., Yamada, K. & Katakai, R. (2003). *Acta Cryst. E* **59**, o1581–o1583.
- Olsen, R. K., Apparao, S. & Bhat, K. L. (1986). *J. Org. Chem.* **51**, 3079–3085.
- Pastuszak, J., Gardner, J. H., Singh, J. & Rich, D. H. (1982). *J. Org. Chem.* **47**, 2982–2987.
- Rigaku (2003). CrystalStructure and RAPID-AUTO. Rigaku Corporation, Akishima, Tokyo 196-8666, Japan.
- Yamada, K., Sato, J., Oku, H. & Katakai, R. (2003). *J. Pept. Res.* **62**, 78–87.